MedPath

An Effectiveness Evaluation for Pathway to Healthy Aging (Path-HA) Care on Health Status of Older Adults

Not Applicable
Recruiting
Conditions
Ageing Well
Interventions
Behavioral: Pathway to Healthy Aging care
Registration Number
NCT06105723
Lead Sponsor
The University of Hong Kong
Brief Summary

The goal of this clinical trial is to provide a scientific evaluation on the effects of a protocol-driven Pathway to Healthy Aging (Path-HA) Program on promoting the health-related quality of life and functional abilities of older adults who are at risk of accelerated aging in the community. Participants will be randomized to one of the two study arms: 1) the intervention group to receive a 14-week Path-HA care intervention; and 2) the control group with no Path-HA care intervention.

Detailed Description

This assessor-blind, randomized controlled trial evaluates the effects of the Pathway to Healthy Aging Program, which is based on the WHO ICOPE model, on the promotion of the health-related quality of life (primary outcome) as well as functional abilities (secondary outcomes) as defined by the WHO-ICOPE among community-dwelling older adults with accelerated aging. Six health domains including locomotor function, vitality, psychological function, cognitive function, social functions, and overall health-related quality of life are measured. A total of 1000 participants will be recruited. Outcome evaluation takes place at baseline, upon the completion of the care program, and at 6 months thereafter to allow the detection of long-term program benefits. In-depth individual interviews will be conducted to solicit the participants' experience and perceived benefits of the program.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
1000
Inclusion Criteria
    1. aged 60 or above,
    1. with at least two risk factors of accelerating aging defined as including reduced physical functioning, malnutrition, depressed mood, loneliness, poor health perception, and presence of geriatric symptoms (e.g. insomnia, pain, etc), based on their health screening results,
    1. community-dwelling,
    1. communicable to engage in health education activity.
Exclusion Criteria
    1. any who is not at or at only one risk factor of accelerating aging,
    1. any who has problems in communicating with the research team.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Path-HA carePathway to Healthy Aging careA 14-week care initiative comprising two phases is provided, which are the 2-week ICOPE-based personalized care planning phase, and the 12-week healthy aging empowerment phase.
Primary Outcome Measures
NameTimeMethod
Health-related quality of lifeChanges from baseline to 3-month and 9-month post-intervention

Measured by the EQ-5D-5L questionnaire (scores range from -0.59 to 1.0), with a higher score indicating better quality of life.

Secondary Outcome Measures
NameTimeMethod
Hand grip strengthChanges from baseline to 3-month and 9-month post-intervention

Measured by hand-held dynamometer in unit of KG. A larger count indicates a greater grip strength.

Sleep qualityChanges from baseline to 3-month and 9-month post-intervention

Measured by Insomnia Severity Index questionnaire (scores range from 0 to 28), with higher scores indicating greater severity of insomnia.

Depressed moodChanges from baseline to 3-month and 9-month post-intervention

Measured by the 15-item Geriatric Depression Scale (scores range from 0 to 15), with a higher score indicating a higher risk of depression.

Social connectednessChanges from baseline to 3-month and 9-month post-intervention

Measured by The 8-item version of Social Connectedness Scale (scores range from 8 to 48), with a higher score indicating a greater sense of social connectedness.

Balancing functionChanges from baseline to 3-month and 9-month post-intervention

Measured by the Timed Up and Go Test in unit of second. A shorter completion time indicates better mobility and balance.

Physical mobility levelChanges from baseline to 3-month and 9-month post-intervention

Measured by the Short Physical Performance Battery (scores range from 0 to 12), with higher scores indicating better physical performance and better mobility functioning.

Nutritional statusChanges from baseline to 3-month and 9-month post-intervention

Measured by the Mini Nutritional Assessment (scores range from 0 to 30), with a lower score indicating a higher risk of malnutrition.

Sarcopenia riskChanges from baseline to 3-month and 9-month post-intervention

Measured by Sarcopenia and calf circumference scale (SARC-CalF scale). The score ranges from 0 to 20 points, with a score ≥ 11 points suggestive of sarcopenia.

Subjective memoryChanges from baseline to 3-month and 9-month post-intervention

Measured by Memory Inventory for the Chinese (scores range from 0 to 108), with higher scores indicating more severe subjective memory loss.

Cognitive functionsChanges from baseline to 3-month and 9-month post-intervention

Measured by the 5-minute Montreal Cognitive Assessment Test (scores range from 0 to 30). A raw score of \< 25 in well-educated persons (education \> 12 years) or a raw score of \< 23 in less-educated persons (education ≤ 12 years) is defined as impaired cognition.

LonelinessChanges from baseline to 3-month and 9-month post-intervention

Measured by The 3-Item UCLA Loneliness Scale (scores range from 3 to 9), with higher scores suggesting a higher level of loneliness.

Trial Locations

Locations (1)

The University of Hong Kong

🇭🇰

Hong Kong, Hong Kong

© Copyright 2025. All Rights Reserved by MedPath